[ad_1] Article content OTTAWA, Ontario — With the release of their National Compensation Guide, BioTalent Canada is helping health and biosciences employers develop a robust talent management strategy to improve…
Tag: Biosciences
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
[ad_1] MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM)…
QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System
[ad_1] Partnership combines QIAGEN’s QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element’s AVITI System users in genomic analysis Element and QIAGEN are advancing genomic applications with innovative technology…
Acquisition or merger possible for Arcadia Biosciences
[ad_1] DAVIS, CALIF. — Arcadia Biosciences has engaged Lake Street Capital Markets, a Minneapolis-based investment bank, to explore strategic opportunities, which may include an acquisition, the sale of the company,…
NFL Biosciences: 2022 full-year business and earnings update
[ad_1] NFL Biosciences: 2022 full-year business and earnings update Phase II/III clinical trial for the drug candidate NFL-101 for smoking cessation: 100% of volunteers recruited. Initial results expected in the…
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. – Merck.com
[ad_1] April 16, 2023 6:00 am ET PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target…
WSJ News Exclusive | Merck in Late-Stage Talks to Acquire Prometheus Biosciences
[ad_1] Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune…
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
[ad_1] – Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors – DNase program progressing…
Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
[ad_1] Pardes Biosciences, Inc Data from ongoing Phase 2 trial evaluating pomotrelvir (formerly known as PBI-0451) for the treatment of COVID-19 expected in the coming weeks Cash to fund operations for…